drugset / Trial / NCT07151690
BCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed Amyloidosis
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, single-arm, single-center clinical study designed to evaluate the efficacy and safety of low-dose BCMA/CD3 bispecific antibody (CM336) in patients newly diagnosed with systemic light chain (AL) amyloidosis.
Timeline
- Start
- 2025-09-04
- Primary completion
- 2026-12-01
- Completion
- 2027-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CM336 | Monoclonal antibody | 40 mg | Subcutaneous |
| Subject | CM336 | Monoclonal antibody | 80 mg | Subcutaneous |